Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial

RCT (n=393) found that deferiprone was non-inferior to deferasirox for treatment success (change in ferritin concentration, 55.2% vs 54.8%). There was no significant difference in serious and drug related adverse events.


The Lancet Haematology